CytomX Therapeutics (CTMX) Capital Expenditures (2014 - 2025)
CytomX Therapeutics (CTMX) posted Capital Expenditures of $201000.0 for Q4 2025, up 258.27% on a QoQ basis from -$127000.0 in Q3 2025, and up 151.25% year-over-year from $80000.0 in Q4 2024.
CytomX Therapeutics (CTMX) Capital Expenditures (2014 - 2025) Analysis & Trends
CytomX Therapeutics' Capital Expenditures history runs 12 years deep, the most recent figure standing at $201000.0 for Q4 2025.
- Quarterly Capital Expenditures rose 151.25% year-over-year to $201000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $101000.0 (down 67.83% YoY) and the FY2025 annual result came in at $220000.0, down 29.03% from the prior year.
- Capital Expenditures was $201000.0 for Q4 2025 at CytomX Therapeutics, up from -$127000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $982000.0 in Q1 2021 and bottomed at -$499000.0 in Q4 2023.
- A 5-year average of $197700.0 and a median of $117000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 261.4% — and 2025, when it slumped 768.42%.
- CytomX Therapeutics' Capital Expenditures stood at $245000.0 in 2021, then slipped by 25.71% to $182000.0 in 2022, then slumped by 374.18% to -$499000.0 in 2023, then soared by 116.03% to $80000.0 in 2024, then jumped by 151.25% to $201000.0 in 2025.
- Business Quant data shows CTMX's Capital Expenditures at $201000.0 in Q4 2025, -$127000.0 in Q3 2025, and $27000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 201,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Dec 31, 2024 | 80,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | -499,000.00 |
| Dec 31, 2023 | -499,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |